



# Measure Applications Partnership Clinician Workgroup In-Person Meeting Agenda

December 9-10, 2015 National Quality Forum Conference Center 1030 15th Street NW, 9th Floor, Washington, DC 20005

# **Remote Participation Instructions:**

# Streaming Audio Online

- Direct your web browser to: <u>http://nqf.commpartners.com</u>
- Under "Enter a Meeting" type in the meeting number: **101837** for Day 1 and for **377963** for Day 2.
- In the "Display Name" field, type in your first and last names and click "Enter Meeting."

Teleconference

• Dial (888) 802-7237 for workgroup members or (877) 303-9138 for public participants; use conference ID code: **72951586** for Day 1 and **72953205** for Day 2 to access the audio platform.

### Accessing Meeting Materials

• Go to <u>http://public.qualityforum.org/MAP/Forms/AllItems.aspx</u> and select the MAP Clinician Workgroup folder

# **Meeting Objectives:**

- Review and provide input on measures under consideration for federal programs applicable to clinicians and other eligible professionals
- Finalize input to the MAP Coordinating Committee on measures for use in federal programs
- Identify gaps in measures for federal clinician quality programs

### Day 1-December 9, 2015

8:30 am	Breakfast
9:00 am	Welcome, Disclosures of Interest, Review Meeting Objectives Bruce Bagley, Workgroup Chair Eric Whitacre, Workgroup Chair Chris Cassel, CEO, NQF Reva Winkler, Senior Director, NQF Ann Hammersmith, General Counsel, NQF
9:20 am	Pre-Rulemaking Opening Remarks Kate Goodrich, CMS
9:40 am	<b>Overview of Pre-Rulemaking Approach</b> Andrew Lyzenga, Senior Project Manager, NQF

#### PAGE 2

Poonam Bal, Project Manager, NQF

- Pre-Rulemaking Timeline
- Approach to decision-making
- Deliberations Process
- Instructions for Voting Process
- 10:00 am Overview of the Medicare Shared Savings Program (MSSP) Rabia Khan, CMS (MSSP) Dr. Winkler
- 10:30 am Break
- 10:45 am Opportunity for Public Comment on Medicare Shared Savings Program measures under consideration

# 11:00 pm Pre-Rulemaking Input on the Medicare Shared Savings Program measures under consideration

Marci Nielsen (Lead Discussant)

Kate Koplan (Lead Discussant)

- Falls: Screening, Risk-Assessment, and Plan of Care to Prevent Future Falls (MUC ID: MUC15-579)
- Advance Care Plan (MUC ID: MUC15-578)
- PQI 91 Prevention Quality Acute Composite (MUC ID: MUC15-577)
- Prevention Quality Indicators 92 Prevention Quality Chronic Composite (MUC ID: MUC15-576)
- Ischemic Vascular Disease All or None Outcome Measure (Optimal Control) (MUC ID: MUC15-275)

### 12:00 pm Lunch

12:30 pm Overview of the Merit-Based Incentive Payment System (MIPS) and Physician Compare (PC) Programs Molly A. MacHarris, CMS (MIPS) Alesia D. Hovatter, CMS (Physician Compare)

Dr. Winkler

1:15 pm Opportunity for Public Comment- Dermatology measures under consideration

#### 1:30 pm Pre-Rulemaking Input on the MIPS and PC measures under consideration- Dermatology Scott Furney (MIPS Lead Discussant) Stephen Friedhoff (MIPS Lead Discussant) Bruce W. Sharman (Discussant)

Bruce W. Sherman (Physician Compare Lead Discussant)

- Non-Melanoma Skin Cancer (NMSC): Biopsy Reporting Time Clinician (MUC ID: MUC15-215)
- NMSC: Biopsy Reporting Time Pathologist (MUC ID: MUC15-216)
- Use Of Mohs Surgery For Superficial Basal Cell Carcinomas On The Trunk (MUC ID: MUC15-178)

# Use of Mohs Surgery For Squamous Cell Carcinoma In Situ And Keratoacanthoma Type - Squamous Cell Carcinoma on The Trunk that are 1 cm or smaller (MUC ID: MUC15-179)

 Use Of Preventive Screening Protocol For Transplant Patients (MUC ID: MUC15-177)

2:15 pm Break

## 2:30 pm Opportunity for Public Comment on Eye Care measures under consideration

## 2:45 pm Pre-Rulemaking Input on the MIPS and PC measures under consideration- Eye Care Scott Friedman (MIPS Lead Discussant) Beth Averbeck (MIPS Lead Discussant) Robert Krughoff (Physician Compare Lead Discussant)

- Glaucoma Intraocular Pressure (IOP) Reduction (MUC ID: MUC15-372)
- Glaucoma Intraocular Pressure (IOP) Reduction Following Laser Trabeculosplasty (MUC ID: MUC15-374)
- Exudative Age-Related Macular Degeneration: Loss of Visual Acuity (MUC ID: MUC15-379)
- Nonexudative Age-Related Macular Degeneration: Loss of Visual Acuity (MUC ID: MUC15-392)
- Diabetic Macular Edema: Loss of Visual Acuity (MUC ID: MUC15-393)
- Corneal Graft Surgery Postoperative improvement in visual acuity to 20/40 or better (MUC ID: MUC15-370)
- Surgery for Acquired Involutional Ptosis: Patients with an improvement of marginal reflex distance (MRD) (MUC ID: MUC15-375)
- Acquired Involutional Entropion: Normalized lid position after surgical repair (MUC ID: MUC15-377)
- Acute Anterior Uveitis: Post-treatment visual acuity (MUC ID: MUC15-394)
- Acute Anterior Uveitis: Post-treatment Grade 0 anterior chamber cells (MUC ID: MUC15-396)
- Chronic Anterior Uveitis: Post-treatment visual acuity (MUC ID: MUC15-397)
- Chronic Anterior Uveitis: Post-treatment Grade 0 anterior chamber cells (MUC ID: MUC15-399)
- 3:45 pm Opportunity for Public Comment on Cancer measures under consideration

# 4:00 pm Pre-Rulemaking Input on the MIPS and PC measures under consideration- Cancer measures under consideration

Janis Orlowski (MIPS Lead Discussant)

Constance Dahlin (MIPS Lead Discussant)

Amy Moyer (Physician Compare Lead Discussant)

- Non-Recommended PSA-Based Screening (MUC ID: MUC15-1019)
- Proportion admitted to hospice for less than 3 days (MUC ID: MUC15-415)
- Minimally invasive surgery performed for patients with endometrial cancer (MUC ID: MUC15-452)

### PAGE 3

### PAGE 4

	<ul> <li>Surgical staging with lymph node removal for any grade 3 and/or myometrial invasion &gt;50% with endometrial cancer (MUC ID: MUC15-459) (Measure removed from consideration by CMS on 12/2/2015)</li> <li>Performance of radical hysterectomy in patients with IB1-IIA cervical cancer who undergo hysterectomy (MUC ID: MUC15-465)</li> <li>Use of brachytherapy for cervical cancer patients treated with primary radiation with curative intent (MUC ID: MUC15-460)</li> <li>Completion of external beam radiation within 60 days for women receiving primary radiotherapy as treatment for locally advanced cervical cancer (LACC) (MUC ID: MUC15-461)</li> <li>Postoperative pelvic radiation with concurrent cisplatin-containing chemotherapy with (or without) brachytherapy for patients with positive pelvic nodes, positive surgical margin, and/or positive parametrium (MUC ID: MUC15-466)</li> <li>Use of concurrent platinum-based chemotherapy (MUC ID: MUC15-463)</li> <li>Platin or taxane administered within 42 days following cytoreduction to women with invasive stage I (grade 3), IC-IV ovarian, fallopian tube, or peritoneal cancer (MUC ID: MUC15-454)</li> <li>Intraperitoneal chemotherapy administered within 42 days of optimal cytoreduction to women with invasive stage III ovarian, fallopian tube, or peritoneal cancer (MUC ID: MUC15-450)</li> </ul>	
4:45 pm	Opportunity for Public Comment	
5:00 pm	Adjourn	
Day 2-December 10, 2015		
8:00 am	Breakfast	
8:30 am	Welcome and Recap of Day 1 Bruce Bagley, Workgroup Chair Eric Whitacre, Workgroup Chair	
8:45 am	Opportunity for Public Comment on Interventional Radiology measures under consideration	
9:00 am	<ul> <li>Pre-Rulemaking Input on the MIPS and PC measures under consideration- Interventional Radiology</li> <li>Paul N. Casale (MIPS Lead Discussant)</li> <li>David J. Seidenwurm (MIPS Lead Discussant)</li> <li>Rachel Grob (Physician Compare Lead Discussant)</li> <li>Rate of adequate percutaneous image-guided biopsy (MUC ID: MUC15-420)</li> <li>Efficacy of uterine artery embolization for symptomatic uterine fibroids (MUC ID: MUC15-423)</li> <li>Common femoral arterial access site complication (MUC ID: MUC15-424)</li> </ul>	

# • 30 Day Stroke and Death Rate for Symptomatic Patients undergoing carotid stent placement (MUC ID: MUC15-402)

- Patient reported outcomes following ilio-femoral venous stenting (MUC ID: MUC15-411)
- Assessment of post-thrombotic syndrome following ilio-femoral venous stenting (MUC ID: MUC15-412)
- Improvement in the Venous Clinical Severity Score after ilio-femoral venous stenting (MUC ID: MUC15-413)

### 10:00 am Break

### 10:15 pm Opportunity for Public Comment on Urogynecology measures under consideration

### 10:30 pm Pre-Rulemaking Input on the MIPS and PC measures under consideration-

Urogynecology

Luther T. Clark (MIPS Lead Discussant) James Pacala (MIPS Lead Discussant) Barb Landreth (Physician Compare Lead Discussant)

- Route of hysterectomy (MUC ID: MUC15-437)
- Over-utilization of mesh in the posterior compartment (MUC ID: MUC15-436)
- Testing for uterine disease prior to obliterative procedures (MUC ID: MUC15-439)
- Verification of Intrinsic Sphincter Deficiency prior to transurethral bulking injection (MUC ID: MUC15-434) (Measure removed from consideration by CMS on 12/2/2015)
- Documentation of offering a trial of conservative management prior to fecal incontinence surgery (MUC ID: MUC15-440)
- Documentation of offering a trial of conservative management prior to urgency incontinence surgery (MUC ID: MUC15-441)

### 11:30 pm Opportunity for Public Comment on Gastroenterology measures under consideration

# 11:45 pm Pre-Rulemaking Input on the MIPS and PC measures under consideration-Gastroenterology

Diane Padden (MIPS Lead Discussant) Peter Briss (MIPS Lead Discussant)

Stephanie Glier (Physician Compare Lead Discussant)

- Surveillance endoscopy for dysplasia in Barrett's Esophagus (MUC ID: MUC15-208)
- Surveillance colonoscopy for dysplasia in Ulcerative Colitis (MUC ID: MUC15-221)
- Surveillance colonoscopy for dysplasia in colonic Crohns Disease (MUC ID: MUC15-221)
- Non-selective beta blocker use in patients with esophageal varices (MUC ID: MUC15-209)
- Hepatitis C Virus (HCV)- Sustained Virological Response (SVR) (MUC ID: MUC15-229)
- Hepatitis B vaccination for patients with chronic Hepatitis C (MUC ID: MUC15-220)
- Hepatitis B vaccination for patients with cirrhosis (MUC ID: MUC15-211)
- Hepatitis A vaccination for patients with cirrhosis (MUC ID: MUC15-210)

### PAGE 5

#### PAGE 6

- Screening endoscopy for varices in patients with cirrhosis (MUC ID: MUC15-251)
- Screening for Hepatoma in patients with Chronic Hepatitis B (MUC ID: MUC15-217)
- 12:30 pm Lunch
- 1:00 pm Opportunity for Public Comment on Miscellaneous measures under consideration

### 1:15 pm Pre-Rulemaking Input on the MIPS and PC measures under consideration- Miscellaneous Topics

Terry Adirim (MIPS Lead Discussant) Winfred Wu (MIPS Lead Discussant) Girma Alemu (MIPS Lead Discussant) Cynthia Pellegrini (Physician Compare Lead Discussant)

- Paired Measure: Depression Utilization of the PHQ-9 Tool; Depression Remission at Six Months; Depression Remission at Twelve Months (MUC ID: MUC15-928)
- PQI 91 Prevention Quality Acute Composite (MUC ID: MUC15-577)
- Prevention Quality Indicators 92 Prevention Quality Chronic Composite (MUC ID: MUC15-576)
- Potential Opioid Overuse (MUC ID: MUC15-1169)
- HIV Screening for Patients with Sexually Transmitted Disease (STD) (MUC ID: MUC15-230)
- New Corneal Injury Not Diagnosed in the Post-Anesthesia Care Unit/Recovery Area (MUC ID: MUC15-296)
- Performance of objective measure of functional hearing status (MUC ID: MUC15-307)
- Patient-Reported Functional Communication (MUC ID: MUC15-313)
- Ischemic Vascular Disease All or None Outcome Measure (Optimal Control) (MUC ID: MUC15-275)
- 2:00 pm Workgroup Discussion Gaps in the Clinician program measure sets

2:30 pm	<ul> <li>Workgroup Discussion – Alignment</li> <li>Alignment of clinician measures across clinician programs</li> <li>Alignment of clinician measures with measures in hospital and PAC/LTC programs</li> </ul>
3:00 pm	Workgroup discussion – Public reporting of clinician measures
3:30 pm	Opportunity for Public Comment

- 3:45 pm Summary of the MAP Clinician Workgroup pre-rulemaking input
- 4:00 pm Adjourn